{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:54:28Z","timestamp":1777452868817,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>According to guidelines all HIV\u2013HBV-coinfected patients should receive tenofovir-based combination antiretroviral therapy (cART). We aimed to investigate uptake and outcomes of tenofovir-based cART among HIV\u2013HBV patients in the EuroSIDA study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All hepatitis B surface antigen (HBsAg)+ patients followed up after 1 March 2002 were included. Changes in the proportion taking tenofovir-based cART over time were described. Poisson regression was used to investigate the relationship between tenofovir use and clinical events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      953 HIV\u2013HBV patients were included. Median age was 41 years and patients were predominantly male (85%), White (82%) and ART-experienced (88%). 697 and 256 were from Western and Eastern Europe, respectively. 55 started cART during follow-up, the proportion starting with CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell count &lt;350 cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      decreased from 85% to 52% in the periods 2002\u20132006 to 2007\u20132015. Tenofovir use, among those taking cART, increased from 4% in 2002 to 73% in 2015. Compared to West, tenofovir use was lower in East in 2005 (7% versus 42%), and remained lower in 2015 (63% versus 76%). Among 602 patients taking tenofovir-based cART during follow-up, 155 (26%) discontinued tenofovir. 27 of all discontinuations were due to adverse effects. Only 14 started entecavir and\/or adefovir after tenofovir discontinuation, whereas 10 started pegylated interferon. Tenofovir use was not significantly associated with lower risk of liver-related clinical events ( n=51), adjusted incidence rate ratio (IRR) 0.64 (95% CI 0.35, 1.18) for comparing patients on tenofovir with those off tenofovir.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although use of tenofovir-based cART among HIV\u2013HBV patients has increased across Europe, a substantial proportion are still starting cART late and are receiving suboptimal HBV therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3218","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T09:44:24Z","timestamp":1515145464000},"page":"405-413","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Uptake of Tenofovir-Based Antiretroviral Therapy among HIV\u2013HBV-Coinfected Patients in the EuroSIDA Study"],"prefix":"10.1177","volume":"23","author":[{"given":"Lars","family":"Peters","sequence":"first","affiliation":[{"name":"CHIP, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Mocroft","sequence":"additional","affiliation":[{"name":"University College London Medical School, Primary Care and Population Sciences, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Grint","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, Department of Infectious Disease Epidemiology, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal-IRYCIS, Infectious Diseases Department, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[{"name":"University Hospital Geneva, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djordje","family":"Jevtovic","sequence":"additional","affiliation":[{"name":"The Institute for Infectious & Tropical Diseases, Belgrade, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Sambatakou","sequence":"additional","affiliation":[{"name":"Athens Medical School, Hippokration General Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[{"name":"Hopital Saint-Antoine, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane De","family":"Wit","sequence":"additional","affiliation":[{"name":"CHU Saint-Pierre Hospital, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"University of Bonn, Department of Medicine I, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Smidt","sequence":"additional","affiliation":[{"name":"Narva AIDS Centre, Kohtla-J\u00e4rve, Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Karpov","sequence":"additional","affiliation":[{"name":"Belarus State Medical University, Minsk, Belarus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Grzeszczuk","sequence":"additional","affiliation":[{"name":"Uniwersytet Medyczny w Bialymstoku, Department of Infectious Diseases, Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesnadarjan","family":"Haziosmanovic","sequence":"additional","affiliation":[{"name":"Klinicki Centar Univerziteta Sarajevo, Sarajevo, Bosnia & Herzegovina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Gottfredsson","sequence":"additional","affiliation":[{"name":"University of Iceland and Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Radoi","sequence":"additional","affiliation":[{"name":"Dr. Victor Babes Hospital, Spitalul de Boli Infectioase si Tropicale, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Kuzovatova","sequence":"additional","affiliation":[{"name":"Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology, Nizhny Novgorod, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[{"name":"Royal London Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lisa","family":"Ridolfo","sequence":"additional","affiliation":[{"name":"Osp. L. Sacco, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Zapirain","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Alava, Vitoria-Gasteiz, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Lundgren","sequence":"additional","affiliation":[{"name":"CHIP, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"bibr1-IMP3218","unstructured":"EMA. Summary of product characteristics \u2013 Viread 123 mg film-coated tablets. (Accessed 6 May 2017.) Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000419\/WC500051737.pdf."},{"key":"bibr2-IMP3218","unstructured":"EMA. Committee for medicinal products for human use post-authorisation summary of positive opinion for Viread. (Accessed 6 May 2017.) Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/000419\/WC500059318.pdf."},{"key":"bibr3-IMP3218","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37061"},{"key":"bibr4-IMP3218","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300525"},{"key":"bibr5-IMP3218","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042184"},{"key":"bibr6-IMP3218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.03.003"},{"key":"bibr7-IMP3218","unstructured":"EACS. Guidelines for the clinical management and treatment of HIV infected adults in Europe. (Accessed 6 May 2017.) Available from http:\/\/www.eacsociety.org\/files\/2007_eacsguidelines-v1-english_oct_madrid_1.pdf."},{"key":"bibr8-IMP3218","unstructured":"EACS. Guidelines Version 8.1 October 2016. (Accessed 6 May 2017.) Available from http:\/\/www.eacsociety.org\/files\/guidelines_8.1-english.pdf."},{"key":"bibr9-IMP3218","unstructured":"CHIP. (Accessed 22 November 2017.) Available from https:\/\/www.chip.dk\/Studies\/EuroSIDA."},{"key":"bibr10-IMP3218","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240201"},{"key":"bibr11-IMP3218","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000674"},{"key":"bibr12-IMP3218","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-S6-S13"},{"key":"bibr13-IMP3218","doi-asserted-by":"publisher","DOI":"10.1310\/hct1202-109"},{"key":"bibr14-IMP3218","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw380"},{"key":"bibr15-IMP3218","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28280"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:30Z","timestamp":1777380750000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.3851\/IMP3218"],"URL":"https:\/\/doi.org\/10.3851\/imp3218","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]}}}